Skip to main content


Key Advantages of Sinnais™ Metronomic Deliverys

In contrast to the current standard of intraventricular drug delivery to the brain in which the therapeutic is delivered in a single bolus repeated at long intervals (of days or weeks), resulting in significant swings in the concentration of the delivered therapeutic, SINNAIS is designed for metronomic delivery, which is the delivery of sub-microliter-level amounts of drugs at consistently repeating rates. SINNAIS’s proprietary, state-of-the-art piezoelectric pump is capable of delivering precise microliter doses according to a preprogrammed and scheduled regimen.

Third-party studies and supporting clinical data have found that metronomic delivery keeps therapeutic drug levels within acceptable ranges and minimizes peak toxicity levels associated with the maximum toxicity of bolus delivery model, and that it also enables keeping a drug within a desired range of concentrations for an extended period of time, which may improve efficacy of treatment and reduce adverse side effects to patients. References to such treatment can be found in both pre-clinical studies and clinical trials.

JNS Thumbnail

Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model

Wang W, Cho HY, Rosenstein-Sisson R, Marín Ramos NI, Price R, Hurth K, Schönthal AH, Hofman FM, Chen TCJ Neurosurg. 2017 Apr 14:1-6. doi: 10.3171/2016.11.JNS161212. [Epub ahead of print]

View on PubMed

JNS Thumbnail

Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note

Chen TC, Napolitano GR, Adell F, Schönthal AH, Shachar Y.J Neurosurg. 2015 Aug;123(2):362-72. doi: 10.3171/2014.10.JNS14343. Epub 2015 May 8.

View on PubMed

Neurosurgical Focus Thumbnail

Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals

Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari VP, Gong A, Howard A, Golden EB, Louie SG, Schönthal AH, Hofman FM, Chen TC.Neurosurg Focus. 2015 Mar;38(3):E8. doi: 10.3171/2015.1.FOCUS14743.

View on PubMed

Benefits of Metronomic Delivery

Clinical data supports the therapy value of intraventricular delivery of drugs into the Cerebrospinal fluid (CSF). Specifically, intraventricular drug delivery is indicated to improve drug efficacy by enabling the drug to reach the various regions of the brain following the cerebrospinal fluid circulatory pathway, thus providing an efficient and uniform drug infusion into the brain. Cognos Therapeutics is a leader in the design and development of a technologically advanced implantable pump, SINNAIS™, which includes a smart shunt adapted to deliver an adjustable volume and concentration of drugs to the ventricles in the brain. The Cognos Therapeutics smart shunt further includes features that enable physicians to utilize metronomic delivery of drugs and obtain parametric data such as temperature, pressure, and PH from the CSF. Notably, metronomic intraventricular drug delivery from SINNAIS™ implanted pump may be applicable in the delivery of various new biotherapeutics to the brain, thus launching a new frontier in clinical therapy.

Neurotherapeutics Thumbnail

A Site-specific, Sustained-release Drug Delivery System for Aneurysmal Subarachnoid Hemmorhage

Daniel Hiinggi, Nima Etminan, Hans Jakob Steiger, Mark Johnson, Melissa Peet, Tom Tice, Kevin Burton, Bruce Hudson, Michele Turner, Angela Stella, Parissa Heshmati, Cara Davis, Herbert J. Faleck, Loch Macdonald

View Article

American Heart Association Journals Thumbnail

Randomized, Open-Label, Phase 1/2a Study to Determinethe Maximum Tolerated Dose of Intraventricular SustainedRelease Nimodipine for Subarachnoid Hemorrhage(NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]) model

Daniel Hanggi, MD; Nima Etminan, MD; Francois Aldrich, MD; Hans Jakob Steiger, MD; Stephan A. Mayer, MD; Michael N. Diringer, MD; Brian L. Hoh, MD; J Mocco, MD; Herbert J. Faleck, DO; R. Loch Macdonald, MD; on behalf of the NEWTON Investigators

View Article

Oncotarget Thumbnail

Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy

Dong Geon, Kim Kang, Yun Jee, Heekyoung Yang, Eric G. Marcusson, Eunju Son, Kyoungmin Lee, Jason K. Sa, Hye Won Lee1, Do-Hyun Nam

View Article

Medscape Thumbnail

Lymphomatous Meningitis in Primary Central Nervous System Lymphoma

Marc C. Chamberlain, M.D.

View Article

Molecular Genetics and Metabolism Thumbnail

Best practices for the use of intracerebroventricular drug delivery devices

Irene Slavca,*, Jessica L. Cohen-Pfefferb, Sridharan GururanganC, Jeanne KrauserC, Daniel A. Limd, Marcos Maldaune, Christoph Schweringf, Adam J. Shaywitzh, Manfred Westphalf

View Article

National Library of Medicine Thumbnail

Metronomic Chemotherapy

Rituparna Maiti

View Article